Latest News and Press Releases

EMPAVELIMD (pegcétacoplan) est le premier traitement autorisé dans le traitement des patients adultes et pédiatriques de 12 ans et plus atteints de glomérulopathie à dépôts de C3 (GC3) ou de...

EMPAVELI® (pegcetacoplan) is the first approved treatment for C3G or primary IC-MPGN for patients 12 years and older in Canada Approval supported by Phase 3 52-week VALIANT study demonstrated reduced...

NASP data highlight reduction in disease burden among people living with uncontrolled gout Gamifant (emapalumab) data showed response rates in patients with MAS in Still’s disease across MAS...

Doptelet Sprinkle (avatrombopag) was approved as an effective formulation for children one year to less than six years. The primary endpoint was met in 27.8% of patients, confirming the efficacy in...

WALTHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi®), today announced that the U.S. Food and Drug Administration...

WALTHAM, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi®), today announced the presentation of four abstracts that...

Sobi will present three abstracts that highlights data from its myelofibrosis treatment option at ASCO.

FDA has granted Fast Track designation to emapalumab-lzsg for the potential first therapeutic option in patients with MAS

WALTHAM, Mass., 08 nov. 2023 (GLOBE NEWSWIRE) -- Sobi Amérique du Nord, la filiale nord-américaine de Swedish Orphan Biovitrum AB (SobiMD), a annoncé aujourd’hui l’approbation par Santé Canada de...

Health Canada Approves DOPTELET (avatrombopag) for Two Indications in Thrombocytopenia